• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Accord Healthcare

Foresee Pharmaceuticals wins CHMP backing for CAMCEVI 21 mg, expanding prostate cancer treatment options in Europe

By Pallavi Madhiraju on March 8, 2026   Pharma & Biotech  

Foresee Pharmaceuticals wins CHMP backing for CAMCEVI 21 mg, expanding prostate cancer treatment options in Europe

CHMP backs CAMCEVI 21 mg for advanced prostate cancer in the EU. Discover what the decision means for androgen deprivation therapy and oncology markets.

Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care

By Pallavi Madhiraju on February 20, 2026   Pharma & Biotech  

Why ImmunityBio’s ANKTIVA European launch could reshape BCG-unresponsive bladder cancer care

ImmunityBio expands ANKTIVA into Europe with Accord Healthcare. Discover what this means for bladder cancer care, regulation, and real-world adoption.

Recent Posts

  • AACR 2026: SingleCell Biotechnology targets oncology’s blind spot with functional single-cell profiling
  • Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?
  • IntoDNA unveils sSTRIDE-NER and sSTRIDE-PARP1 at AACR 2026, can functional DNA repair assays reshape precision oncology?
  • Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?
  • Akamis Bio AACR 2026 update: what early NG-350A data could mean for organ preservation
  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes